HR Execs on the Move

Colucid

www.colucid.com

 
CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company`s investors include Pappas Ventures, Domain Associates, Care Capital, Novo Ventures, Triathalon Medical Ventures, TVM Life Science Management, Auriga Partners and Pearl Street Venture Funds. The company is developing oral lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain by health care professionals.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.colucid.com
  • P.O. Box 425227
    Cambridge, MA USA 02142
  • Phone: 781.365.2596

Executives

Name Title Contact Details

Similar Companies

Kamm Consulting

Kamm Consulting is a Apex, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Brogan Pharmaceuticals

Brogan Pharmaceuticals is a Crown Point, IN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Catalyst Pharmaceuticals

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), infantile spasms, and Tourette`s Disorder.

Institute for OneWorld Health

Institute for OneWorld Health is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Pharvaris

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.